Notably, best discrimination was obtained between patients with and without recurrent cancer when patients were stratified for post-therapeutic PD-L1+ CD49+ CD133+ CTC numbers ≥ 5 or ≥ 2/ml, respectively. This evidence concerns the gene PROM1 and cancer.